Cholesterol and triglycerides is the main area connected here, and any felt benefit should be read together with the human evidence base.
The 56.0 score includes research signals from patient or disease contexts. General supplement evidence is not repeated enough, so the B tier remains conservative.
Representative tier calculated from paper evidence that passed the collection audit.
The representative ingredient tier is calculated from these target-level evidence groups.
Potential benefit studied in Blood lipids. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
This card is closer to a measured biomarker or lab outcome than a directly felt user benefit. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
This is based on lab markers such as blood levels, deficiency correction, or absorption. Read it separately from directly felt outcomes.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
This card is closer to a measured biomarker or lab outcome than a directly felt user benefit. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
These findings come from sperm, semen, or hormone markers such as testosterone, LH, FSH, and inhibin B. They are closer to research measurements than a directly felt benefit. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
This range includes studies in specific patient groups. It is not a general dose or recommendation.
Findings from studies of this ingredient alone are separated from findings involving another supplement or medication.
Side effects reported for the ingredient alone are separated from findings involving another supplement or medication.
Symptoms or adverse events reported in studies of this ingredient without another active ingredient.
Paper IDs and full lists are private. Only study types and summaries are shown.
Findings indicate that BBR, in addition to upregulating the LDLR, inhibits lipid synthesis in human hepatocytes through the activation of AMPK, which could account for the strong reduction of plasma TGs observed with this drug in clinical trials.
It is demonstrated in a randomized controlled trial that effects of berberine, a plant alkaloid known to lower blood glucose, may be explained by the inhibition of Ruminococcus bromii mediated biotransformation of the bile acid deoxycholic acid.
Examples in the pharmacokinetics field, obesity, hyperlipidaemia, diabetes, cancer, inflammatory disease conditions, etc are used to show the link between the gut microbiota and the polypharmacology of berberine.
It is shown that the gut microbiota converts BBR into its absorbable form of dihydroberberine (dhBBR), which has an intestinal absorption rate 5-fold that of BBR in animals.
Investigation of the anti-colitis activity and potential mechanism of oxyberberine (OBB), a novel gut microbiota metabolite of BBR, in DSS-induced colitis mice revealed that OBB effectively improved D SS-induced experimental colitis, at least partly through ma
A deeper understanding of berberine's effectiveness is delves into by integrating network pharmacology and molecular docking techniques in the context of treating inflammatory diseases, providing guidance and reference for berberine's subsequent revelation of